s. aureus type 5 & 8 capsular polysaccharide vaccine

The S. aureus Type 5 & 8 Capsular Polysaccharide Vaccine is a conjugate vaccine developed to prevent infections caused by Staphylococcus aureus, particularly bacteremia in high-risk populations such as hemodialysis patients. It consists of the two most prevalent capsular polysaccharides (types 5 and 8) conjugated to a carrier protein to enhance immunogenicity. The mechanism of action involves inducing opsonophagocytic antibodies that target the bacterial capsule, thereby promoting clearance of the pathogen by the immune system[1][3][6]. Early clinical studies showed promise in reducing bacteremia for up to several months post-immunization; however, later large-scale trials did not demonstrate significant efficacy in preventing infection[4][7].

Brand names

StaphVAX

Other names

Staphylococcus aureus types 5 and 8 capsular polysaccharide conjugate vaccineS. aureus CP5/CP8 conjugate vaccineStaphVax